Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Whittaker

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Cancer Cell|July 9, 2010
All roads lead to the ribosomeSteven Whittaker, Matthew Martin, Richard Marais
Cancer Cell|March 14, 2007
The EGF receptor Hokey-CokeyDan Niculescu-Duvaz, Steven Whittaker, Caroline Springer, et al.
Journal of Biomolecular Screening|December 20, 2005
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screenYvette Newbatt, Samantha Burns, Robert Hayward, et al.
Science Translational Medicine|June 12, 2010
Gatekeeper mutations mediate resistance to BRAF-targeted therapiesSteven Whittaker, Ruth Kirk, Robert Hayward, et al.
Bioorganic & Medicinal Chemistry|February 5, 2013
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituentsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.
Cell|February 10, 2010
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFSonja J Heidorn, Carla Milagre, Steven Whittaker, et al.
Cancer Research|September 3, 2010
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAFSteven Whittaker, Delphine Ménard, Ruth Kirk, et al.
Journal of Medicinal Chemistry|February 13, 2010
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ringArnaud Nourry, Alfonso Zambon, Lawrence Davies, et al.
Journal of Medicinal Chemistry|July 6, 2010
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitorsAlfonso Zambon, Delphine Ménard, Bart M J M Suijkerbuijk, et al.
Bioorganic & Medicinal Chemistry|October 11, 2011
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitorsStuart C Wilson, Butrus Atrash, Clare Barlow, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cancer Cell|July 9, 2010
All roads lead to the ribosomeSteven Whittaker, Matthew Martin, Richard Marais
Cancer Cell|March 14, 2007
The EGF receptor Hokey-CokeyDan Niculescu-Duvaz, Steven Whittaker, Caroline Springer, et al.
Journal of Biomolecular Screening|December 20, 2005
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screenYvette Newbatt, Samantha Burns, Robert Hayward, et al.
Science Translational Medicine|June 12, 2010
Gatekeeper mutations mediate resistance to BRAF-targeted therapiesSteven Whittaker, Ruth Kirk, Robert Hayward, et al.
Bioorganic & Medicinal Chemistry|February 5, 2013
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituentsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.
Cell|February 10, 2010
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFSonja J Heidorn, Carla Milagre, Steven Whittaker, et al.
Cancer Research|September 3, 2010
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAFSteven Whittaker, Delphine Ménard, Ruth Kirk, et al.
Journal of Medicinal Chemistry|February 13, 2010
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ringArnaud Nourry, Alfonso Zambon, Lawrence Davies, et al.
Journal of Medicinal Chemistry|July 6, 2010
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitorsAlfonso Zambon, Delphine Ménard, Bart M J M Suijkerbuijk, et al.
Bioorganic & Medicinal Chemistry|October 11, 2011
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitorsStuart C Wilson, Butrus Atrash, Clare Barlow, et al.
Pageof 2